SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Roof who wrote (360)9/12/1997 11:43:00 PM
From: Rainforest   of 1972
 
Jim, 2 mil of license fees in the bank and another 35 mil probably on the way PLUS royalties if they can make anything of it. That kind of money could make it unnecessary for them to do another stock offering to continue to fund their allovectin and leuvectin trials. Not to mention that this is confirmation of Merck's continued interest in Vical's technology which was put somewhat in question by Dr. Liu's departure for Chiron and by Merck's silence as to the results of its phase 1 vaccine studies. IMHO this news is huge and will boost the price by a couple of bucks Monday and will lead to a steady rise to the $20 level within a short time, especially if the second phase 2 skin cancer trials, the results of which are due to be announced later this year, continue to show encouraging progress.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News